[{"orgOrder":0,"company":"Reachbio Research Labs","sponsor":"Discovery Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Hematology","graph2":"Discovery","graph3":"Reachbio Research Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Reachbio Research Labs \/ Discovery Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Reachbio Research Labs \/ Discovery Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Reachbio Research Labs

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The Acquisition aims to enhance cell biology capabilities and accelerate assessments of potential new drug targets in hematologic diseases, cell and gene therapy, immunology, oncology, and immuno-oncology.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 11, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Hematology

                          Highest Development Status : Discovery

                          Sponsor : Discovery Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank